January 24th 2025
OnabotulinumtoxinA injections are safe and well-tolerated in children and adolescents, with no patients reporting severe adverse events across all published studies and common adverse events predominantly comprising minor injection-site reactions.
Get direct access to interviews with experts, as well as the latest data and clinical news updates, straight from the conference floor in Los Angeles.
Individualizing Treatment for Patients with Generalized Myasthenia Gravis
View More
A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden
March 1, 2025
Register Now!
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders
View More
BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
FDA Accepts sNDA for Higher Dosing Regimen of Nusinersen for Spinal Muscular Atrophy
In the phase 2/3 DEVOTE study, a higher dose of nusinersen met its primary end point at 6 months, achieving a statistically significant improvement in motor function among treatment-naïve symptomatic infants with SMA.
Insights From AES 2024: Advancements and Challenges in Epilepsy Care
Leah Blank, MD, an assistant professor of neurology, population health, science, and policy at the Icahn School of Medicine provided commentary on some of the experience and positive movement from the 2024 American Epilepsy Society Annual Meeting.
Emerging Challenges and Opportunities in Spine Health: A Comprehensive Overview
Robert Rothrock, MD, a spinal neurosurgeon at Baptist Health Miami Neuroscience Institute, provided commentary on key topics in spine health amid the 2025 Baptist Health Spine Symposium.
Differences in Gray Matter Structure May Help Distinguish Multiple Sclerosis From NMOSD
These findings underscore the potential of advanced imaging technologies to detect subtle gray matter differences, aiding in the accurate differentiation between MS and NMOSD.
FDA Grants Priority Review to FcRn Inhibitor Nipocalimab for Myasthenia Gravis
Nipocalimab’s biologics license application is supported by the phase 3 Vivacity-MG3 trial, in which the agent demonstrated superiority over placebo plus standard-of-care over a 24-week period.
Exploring the Changing Diagnosis and Treatments of Neuromyelitis Optica Spectrum Disorder
January 17th 2025Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune CNS condition with distinct subtypes—AQP4-IgG positive, MOGAD, and double-negative—each requiring tailored diagnostic and treatment approaches.
Cell Therapy Bemdaneprocel Advances to Phases 3 Registrational Trial in Parkinson Disease
The newly announced sham surgery-controlled trial will include 102 patients with moderate PD testing several end points, such as change in ON-time without troublesome dyskinesia, over a 78-week period.
NeuroVoices: Nigel Bunnett, PhD, BSc, on Identifying a Novel Therapeutic Target for Chronic Pain
The professor and chair of the Department of Molecular Pathobiology at NYU College of Dentistry discussed groundbreaking research on chronic pain, focusing on the discovery of new mechanisms involving nerve growth factor and its receptors.